The recent resurgence in microbial fermentation for biologics production can be attributed to many factors. Advances in biochemistry and a growing understanding of when glycosylation is not needed, improved capabilities for modification of naked proteins, the emergence of new protein formats and scaffolds well-suited to this production technology, and its applicability to DNA plasmid manufacturing are among them. Successful optimization efforts result in scalable fermentation processes that not only afford high titers and productivity, but also exhibit a high level of robustness and reliability.
